UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement | |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |
| ☐ | Definitive Proxy Statement | |
| ☒ | Definitive Additional Materials | |
| ☐ | Soliciting Material under §240.14a-12 |
United Therapeutics Corporation
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| ☒ | No fee required. | ||
| ☐ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. | ||
| (1) | Title of each class of securities to which transaction applies: | ||
| (2) | Aggregate number of securities to which transaction applies: | ||
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): | ||
| (4) | Proposed maximum aggregate value of transaction: | ||
| (5) | Total fee paid: | ||
| ☐ | Fee paid previously with preliminary materials. | ||
| ☐ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. | ||
| (1) | Amount Previously Paid: | ||
| (2) | Form, Schedule or Registration Statement No.: | ||
| (3) | Filing Party: | ||
| (4) | Date Filed: | ||
|
1735 CONNECTICUT AVENUE, NW WASHINGTON, DC 20009 |
Your Vote Counts! UNITED THERAPEUTICS CORPORATION
2021 Annual Meeting |
|||
 |
||||
| | ||||
| D48156-P54298 | ||||
|
|
||||
You invested in UNITED THERAPEUTICS CORPORATION and it’s time to vote!
You have the right to vote on proposals being presented at the Annual Meeting. THIS IS AN IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIAL FOR THE SHAREHOLDER MEETING TO BE HELD ON JUNE 25, 2021.
Get informed before you vote
View the Annual Report on Form 10-K, the Proxy Statement, and the form of proxy online OR you can receive a free paper or email copy of the proxy material(s) by requesting prior to June 11, 2021. If you would like to request a copy of the proxy material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.
 |
For complete information and to vote, visit www.ProxyVote.com | |||
|
Control # |
 | |||
Smartphone users Point your camera here and |
 |
Vote Virtually at the Meeting* Date: June 25, 2021 |
 |
Location: Virtual Annual Meeting of Shareholders conducted exclusively via live audio webcast at: www.virtualshareholdermeeting.com/UTHR2021 | |
| * | Please check the proxy materials for any special requirements for attending the virtual meeting. |
V1
| Vote at www.ProxyVote.com |
THIS IS NOT A VOTABLE BALLOT
You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. Please follow the instructions on the reverse side to vote these important matters.
| Board | |||
| Voting Items | Recommends | ||
| 1. | Election of Directors | ||
| Nominees: | |||
| 1a. | Katherine Klein |
 |
For |
| 1b. | Ray Kurzweil |
|
For |
| 1c. | Linda Maxwell |
|
For |
| 1d. | Martine Rothblatt |
|
For |
| 1e. | Louis Sullivan |
|
For |
| 2. | Advisory resolution to approve executive compensation. |
|
For |
| 3. | Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan. |
|
For |
| 4. | Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2021. |
|
For |
NOTE: Such other business as may properly come before the meeting or any adjournment thereof. |
|||
| Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Sign up for E-delivery”. |
D48157-P54298